CANBRIDGE-B (01228) surged over 19% again, with cumulative gains exceeding 2000% year-to-date. As of press time, the stock was up 15.51% to HK$2.83, with turnover of HK$66.91 million.

On the news front, the National Healthcare Security Administration established a commercial insurance innovative drug directory for the first time and officially launched the application process on July 11. Three products from CANBRIDGE-B - Goreddy (Velaglucerase beta for injection), Migrebat (Lomitapide oral solution), and Harzis (Idursulfase beta injection) - passed the initial review on August 12, potentially accelerating market access.

Market participants noted that passing the initial review list holds significant importance for CANBRIDGE-B. Assuming inclusion in the commercial insurance innovative drug directory, the drugs would receive support from commercial insurance, potentially reducing patients' financial burden and thereby improving product accessibility.

Additionally, on August 13, CANBRIDGE-B announced a share subscription agreement with Baiyouhui Medical. Under the agreement, Baiyouhui Medical will invest HK$100 million to subscribe for CANBRIDGE-B shares. Simultaneously, both CANBRIDGE-B and Baiyouhui Medical signed an exclusive commercialization service agreement to further deepen strategic collaboration. According to the agreement, subsidiaries of Baiyouhui Medical will obtain promotional rights for specific products under CANBRIDGE-B in mainland China, Hong Kong, and Macau.